赔钱机场官网-赔钱机场网址-赔钱机场节点官网-赔钱机场加速器官网-赔钱机场最新网站-赔钱机场

There is a pressing unmet need for more effective treatments of Pulmonary Arterial Hypertension. A progressive disease caused by cell proliferation in lung blood vessels, PAH (high blood pressure in lung arteries) can adversely affect the heart.
More

赔钱机场官网-赔钱机场网址-赔钱机场节点官网-赔钱机场加速器官网-赔钱机场最新网站-赔钱机场

We have developed a new class of inhalable drugs to decrease cell proliferation, instead of merely “relaxing” pulmonary arteries as today’s vasodilators do. Our hope after clinical trials is to prove greater efficacy with fewer side effects.
More

赔钱机场官网-赔钱机场网址-赔钱机场节点官网-赔钱机场加速器官网-赔钱机场最新网站-赔钱机场

In solving the unique problems of our own pulmonary drug research, Pulmokine has developed patented inhalation systems and preclinical efficacy solutions that we are making available to the pulmonary drug development community.
酸酸乳节点网站